Why Does Activin A Have Both Protective and Pathological Effects in the Brain? Mechanistic Research and Targeted Delivery Challenges
Protective and pathological effects coexist in signaling
Activin A has both protective and pathological effects in the central nervous system, and this duality complicates therapeutic development. A review in Neural Regeneration Research outlines research technologies for examining cell types and the time and place at which signals act, along with delivery strategies to connect mechanistic insight to treatment development.
The central question is under what conditions Activin A has protective or pathological effects. The authors present a research framework for defining its roles in neuroprotection, inflammation, and repair across ischemic stroke, neurodegenerative diseases, glioma, epilepsy, and traumatic brain injury. Because the article reviews applications and future directions for several technologies, it should not be interpreted as evidence that a single integrated treatment platform has demonstrated efficacy in these diseases.
From receptor function to communication between cells
The technologies discussed in the review address different questions. CRISPR-based gene editing is used to test the roles of key receptors, such as ACVR1B, during remyelination. Remyelination is the process by which the myelin sheath around nerve fibers forms again. Establishing receptor function can help examine the relationship between Activin A signaling and repair, but the provided abstract does not specify the models, experimental manipulation conditions, or effect sizes for the relevant experiments.
Organoids and organ-on-a-chip systems are described as methods for modeling human-specific interactions between cells. Spatial and single-cell multi-omics analyze expression patterns and networks of communication between cells. Optogenetics and chemogenetics are presented as tools for precisely controlling signaling pathway activity across time and space.
The rationale for connecting these technologies is to understand receptor function, relationships between cells, and when signals act together. The idea is to study the roles of Activin A in different disease contexts by examining which responses occur in which cells and by modulating signaling activity. However, the abstract gives no quantitative threshold that distinguishes neuroprotection from inflammation and offers no performance comparisons between technologies. Nor does it report that protective and pathological effects have been completely separated.
From mechanistic insight to local modulation and targeted delivery
Building on these mechanistic studies, the review discusses local modulation using adeno-associated virus (AAV)-mediated gene therapy and nanodelivery systems for targeted transport of biologics. It identifies roles for artificial intelligence (AI) in designing ligands to cross the blood–brain barrier (BBB) and optimizing smart nanocarriers. The proposed direction is to connect research into where specific signals should be modulated with technologies for delivering agents to those sites.
The authors contrast preclinical data with the current clinical development landscape, which is weighted toward peripheral diseases, and propose combining tools for decoding mechanisms with AI-based delivery platforms as a path for future progress. This is a proposal for therapeutic development; it does not mean that this review newly demonstrated improved BBB penetration efficiency or the elimination of off-target toxicity.
The available material is limited to bibliographic information and the abstract. Assessing the experimental conditions and performance of individual technologies requires consulting the full text and cited studies. Efficacy in patients, human safety, the results of individual clinical trials, and any shortening of regulatory approval timelines cannot be assessed from these materials.
Source: Bibliographic information and abstract of the review indexed in Europe PMC.
Molecular Neurobiology, Published May 2026.
Summary: Resolving the historical functional dualities where Activin A simultaneously triggers neuroprotective cascades and pathological tissue degeneration within the central nervous system, this comprehensive review integrates multi-modal bioengineering workflows to decode context-specific signaling profiles. By implementing CRISPR-based target screens to validate key receptors like ACVR1B alongside spatial and single-cell multi-omics, the platform maps discrete cellular communication networks. Formulated within organoid-on-a-chip microfluidic systems and manipulated via optogenetic and chemogenetic temporal switches, the framework quantifies transduction thresholds across ischemic stroke, glioma, and traumatic brain injury models. Linking these insights with artificial intelligence-engineered, blood-brain barrier-permeable nanocarriers and adeno-associated virus (AAV) gene delivery vectors provides a scalable computational baseline for prospective universal neuroprotection and high-throughput translational screening.
The review points to a research direction for Activin A-targeted therapies that considers not only signal strength but also the cells in which the signal acts and when it acts. For example, researchers exploring candidates related to remyelination could test ACVR1B function and examine responses between human cells in organoids or organ-on-a-chip systems. Connecting signaling modulation studies with local gene delivery or nanocarrier design is another direction discussed in the review. These are not validated treatment procedures. Further evidence is needed to distinguish protective from pathological effects under disease-specific conditions and to establish delivery performance and safety before practical applications can be assessed.